Providence Business News

Embrace Home Loans' Marcos Sanchez Named a 2022 Top Latino Originator by National Association of Hispanic Real Estate Professionals

Retrieved on:

Tuesday, June 28, 2022

Embrace, Sánchez, Industry, Embrace Home Loans, District, Providence Business News, News, The Last Best Place, National Association, Fortune, Most, Real estate, Club

MIDDLETOWN, R.I., June 28, 2022 /PRNewswire/ -- Embrace Home Loans, a top-ranked national mortgage lender, announces that Marcos Sanchez, manager of its Sandy Spring, Maryland branch, has again been named one of the top 250 Latino mortgage originators in the U.S. by the National Association of Hispanic Real Estate Professionals (NAHREP). This marks the seventh consecutive year Sanchez has received this honor from the NAHREP.

Key Points:

MIDDLETOWN, R.I., June 28, 2022 /PRNewswire/ -- Embrace Home Loans , a top-ranked national mortgage lender, announces that Marcos Sanchez, manager of its Sandy Spring, Maryland branch, has again been named one of the top 250 Latino mortgage originators in the U.S. by the National Association of Hispanic Real Estate Professionals (NAHREP).
"It's a great honor to once again be named a top Latino originator," said Sanchez.
"Marcos consistently exceeds expectations here at Embrace," said Tim Higgins, regional manager at Embrace Home Loans.
Sanchez and the other honorees will be recognized at theNAHREP National Conventionat the L'ATTITUDE conference inSan Diego, September 22 through 25, 2022.

Rubius Therapeutics Presents Updated Data from its Type 1 Diabetes Preclinical Program at the Federation of Clinical Immunology Societies (FOCIS) 2022 Annual Meeting

Retrieved on:

Wednesday, June 22, 2022

CAMBRIDGE, Mass., June 22, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced updated preclinical data for its type 1 diabetes program at the FOCIS 2022 Annual Meeting in San Francisco, CA, June 21-24, 2022.

Key Points:

Rubius Therapeutics is a clinical-stage biopharmaceutical company developing a new class of medicines called Red Cell Therapeutics.
Rubius initial focus is to advance RCT product candidates for the treatment of cancer and autoimmune diseases by leveraging two distinct therapeutic modalities potent cell-cell interaction and tolerance induction.
For more information, visit www.rubiustx.com , follow us on Twitter or LinkedIn or like us on Facebook .
We caution you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made.

Embrace Home Loans Named #1 Place to Work by Providence Business News

Retrieved on:

Wednesday, June 15, 2022

FHA, Fortune, National Mortgage News, Fannie Mae, Providence Business News, CEO, Embrace Home Loans, PBN, News, The Last Best Place, Most, Business News, Freddie Mac, Embrace, District, Real estate, Management

MIDDLETOWN, R.I., June 15, 2022 /PRNewswire/ -- Embrace Home Loans, a top-ranked national mortgage lender, has been ranked number one in Providence Business News' (PBN's) 2022 Best Places to Work awards list. Embrace ranked first in the large employer category, or companies with 150-499 employees in the region.

Key Points:

"We're delighted to be named the top company on PBN's Best Place to Work list," said Dennis Hardiman, CEO of Embrace Home Loans.
"We work hard to make Embrace a great place to come to work each day and we provide our employees with all the tools they need to thrive.
"Embrace has always made it a top priority to put its customers first," Providence Business News reported in its coverage of Embrace Home Loans when announcing the awards list.
Embrace Home Loans is a Fannie Mae, Freddie Mac, FHA and VA lender that processes, underwrites, funds and closes all its loans in-house.

Washington Trust Named as One of Rhode Island's Best Places to Work for Twelfth Consecutive Year

Retrieved on:

Monday, June 13, 2022

Washington Trust was also presented with the 'Community Spirit Award' at the event for the team's enthusiasm and company pride.

Key Points:

Washington Trust was also presented with the 'Community Spirit Award' at the event for the team's enthusiasm and company pride.
"We're proud to be considered an employer of choice and are excited to have been named to the list of Rhode Island's Best Places to Work for the twelfth consecutive time," said Edward O.
The Best Places to Work Awards program is designed to identify, recognize, and honor the best places of employment in Rhode Island through a review of various HR policies and employee satisfaction survey results.
The Washington Trust Company is a subsidiary of Washington Trust Bancorp, Inc., (NASDAQ: WASH).

Rubius Therapeutics to Present at the Jefferies Global Healthcare Conference

Retrieved on:

Wednesday, June 1, 2022

Rubius, The Boston Globe, Degenerative disease, EDT, Conference, RED, El Rubius, LinkedIn, News, Investor, Nasdaq, Providence Business News, Therapy, GLOBE, Twitter, Red Cell, Cancer, Pharmaceutical industry, Facebook

A live audio webcast will be available within the Investors & Media section of the Rubius Therapeutics website.

Key Points:

A live audio webcast will be available within the Investors & Media section of the Rubius Therapeutics website.
An archived replay will be accessible for 90 days following the event.
Rubius Therapeutics is a clinical-stage biopharmaceutical company developing a new class of medicines called Red Cell Therapeutics.
Rubius initial focus is to advance RCT product candidates for the treatment of cancer and autoimmune diseases by leveraging two distinct therapeutic modalities potent cell-cell interaction and tolerance induction.

InsureMyTrip's Senior Vice President Named a 'Woman to Watch' by Providence Business News

Retrieved on:

Friday, June 3, 2022

Woman, Generation, PBN, Product-service system, Business development, News, CEO, Government, Mentorship, Travel, Female, Senior, Providence Business News, Business News, Fort Nonsense (Morristown, New Jersey), Vocabulary, Management, Morrow

WARWICK, R.I., June 3, 2022 /PRNewswire/ -- Providence Business News (PBN) named InsureMyTrip Senior Vice President, Suzanne Morrow, the "Professional Services Woman to Watch".

Key Points:

WARWICK, R.I., June 3, 2022 /PRNewswire/ -- Providence Business News (PBN) named InsureMyTrip Senior Vice President, Suzanne Morrow, the "Professional Services Woman to Watch".
The recognition is part of PBN's 2022 Business Women Awards Program which honors the success of women in various industries.
"I am honored to be named a Woman to Watch among such inspirational and amazing women in business," says Morrow.
She worked her way up to Director of Product Services, then Vice President of Business Development before being promoted to her current role as InsureMyTrip's first female Senior Vice President.

Rubius Therapeutics to Present Trials in Progress Poster for the Phase 1/2 Clinical Trial of RTX-224 in Select Advanced Solid Tumors at the 2022 American Society of Clinical Oncology Annual Meeting

Retrieved on:

Thursday, May 26, 2022

The trial will also assess pharmacodynamic changes in immune cell populations relative to baseline and anti-tumor activity.

Key Points:

The trial will also assess pharmacodynamic changes in immune cell populations relative to baseline and anti-tumor activity.
The study will include a monotherapy dose escalation phase followed by an expansion phase in specified tumor types during the Phase 2 portion of the trial.
Rubius Therapeutics is a clinical-stage biopharmaceutical company developing a new class of medicines called Red Cell Therapeutics.
We caution you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made.

Rubius Therapeutics Appoints Noubar Afeyan as Chairman of its Board of Directors

Retrieved on:

Tuesday, May 24, 2022

Since we founded Rubius Therapeutics in FlagshipLabs in 2014, my conviction in the transformative potential of the RED PLATFORM to benefit patients has significantly grown, said Dr. Afeyan.

Key Points:

Since we founded Rubius Therapeutics in FlagshipLabs in 2014, my conviction in the transformative potential of the RED PLATFORM to benefit patients has significantly grown, said Dr. Afeyan.
Given the programmable nature of the platform, I expect we will enable additional therapeutics modalities to modulate the immune system.
Currently, he sits on several private and public company boards, including Moderna, Omega Therapeutics, Generate Biomedicines, Rubius Therapeutics and Tessera Therapeutics.
Rubius Therapeutics is a clinical-stage biopharmaceutical company developing a new class of medicines called Red Cell Therapeutics.

Mehdi Pirzadeh Joins Rockville, MD Office of Embrace Home Loans

Retrieved on:

Wednesday, May 18, 2022

MIDDLETOWN, R.I., May 18, 2022 /PRNewswire/ -- Embrace Home Loans, a leading national mortgage lender, announced that Mehdi Pirzadeh has been named senior loan officer, vice president in the company's Rockville, MD office. Pirzadeh is a top-producing loan originator who previously worked for Embrace and recently returned, drawn back by the company's commitment to customer service and giving back to the community.

Key Points:

MIDDLETOWN, R.I., May 18, 2022 /PRNewswire/ -- Embrace Home Loans , a leading national mortgage lender, announced that Mehdi Pirzadeh has been named senior loan officer, vice president in the company's Rockville, MD office.
"We are delighted to welcome Mehdi back to Embrace," said Guy Silas, branch manager of Embrace's Rockville, MD office.
Pirzadeh began his 22-year career in the mortgage industry as a mortgage originator at Mason Dixon Funding, which was acquired by Embrace Home Loans in 2009.
A Fannie Mae, Freddie Mac, FHA and VA lender, Embrace also originates non-conforming loans, including jumbo and other unconventional loans.

Rubius Therapeutics to Announce First Quarter 2022 Financial Results

Retrieved on:

Tuesday, April 26, 2022

Rubius, Providence Business News, Red Cell, The Boston Globe, RED, Twitter, News, GLOBE, LinkedIn, Nasdaq, Degenerative disease, Therapy, Cancer, Pharmaceutical industry, Facebook

CAMBRIDGE, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics for the treatment of cancer and autoimmune diseases, today announced plans to report first quarter financial results onTuesday, May 10, 2022, before market open.

Key Points:

CAMBRIDGE, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics for the treatment of cancer and autoimmune diseases, today announced plans to report first quarter financial results onTuesday, May 10, 2022, before market open.
The company will not be hosting a teleconference in conjunction with its financial results press release.
Rubius Therapeutics is a clinical-stage biopharmaceutical company developing a new class of medicines called Red Cell Therapeutics.
Rubius initial focus is to advance RCT product candidates for the treatment of cancer and autoimmune diseases by leveraging two distinct therapeutic modalities potent cell-cell interaction and tolerance induction.